Compare · LLY vs REVB
LLY vs REVB
Side-by-side comparison of Eli Lilly and Company (LLY) and Revelation Biosciences Inc. (REVB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and REVB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.16T, about 291537.4x REVB ($4.0M).
- LLY has been more active in the news (17 items in the past 4 weeks vs 12 for REVB).
- LLY has more recent analyst coverage (25 ratings vs 1 for REVB).
- Company
- Eli Lilly and Company
- Revelation Biosciences Inc.
- Price
- $1215.58-1.45%
- $0.97-12.96%
- Market cap
- $1.16T
- $4.0M
- 1M return
- -0.51%
- -
- 1Y return
- +65.22%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 17
- 12
- Recent ratings
- 25
- 1
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Revelation Biosciences Inc.
Revelation Biosciences, Inc., a clinical -stage biopharmaceutical company, focuses on the development or commercialization of innate immune system therapeutics and diagnostics. The company's lead therapeutic candidate is REVTx-99, an anti -viral nasal drop for the prevention or treatment of respiratory viral infections, as well as for the prevention or treatment of nasal congestion due to allergies or chronic rhinosinusitis. Its lead diagnostic is the REVDx -501, a rapid test kit to detect various respiratory viral infections. The company also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination. Revelation Biosciences, Inc. was founded in 2019 and is headquartered in San Diego, California.
Latest LLY
- Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)
- Director Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)
- Director Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)
- EVP & President, LLY Int'l Jonsson Patrik sold $7,638,150 worth of shares (6,500 units at $1,175.10) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 54,147 units (SEC Form 4)
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
Latest REVB
- Revelation Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
- Chief Financial Officer Zygmont Chester Stanley Iii was granted 208,073 shares, gifted 208,073 shares and received a gift of 208,073 shares (SEC Form 4)
- Director Chawla Lakhmir S was granted 32,011 shares, increasing direct ownership by 263% to 44,169 units (SEC Form 4)
- Director Roper Jess was granted 32,011 shares, increasing direct ownership by 250% to 44,839 units (SEC Form 4)
- Chief Executive Officer Rolke James was granted 208,076 shares, increasing direct ownership by 97% to 422,814 units (SEC Form 4)
- Director Carver Jennifer was granted 32,011 shares, increasing direct ownership by 251% to 44,769 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Revelation Biosciences Inc.
- Revelation Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026